PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
You may also be interested in...
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
Sponsor representatives also want postmarketing discussions moved to earlier in the assessment cycle.
Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?